Adam Rock, MD
Medical Oncology · Duarte, CANPI 1477907715
Payments from drug & device makers
Across 198 payments — averaging $13,719 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$1M
- Taiho Oncology, Inc.$761K
- Boehringer Ingelheim Pharma GmbH & Co.kg$474K
- Merck$315K
- AbbVie$93K
- Coherus Oncology, Inc.$51K
- plus $6K from 25 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 14 | $1,015,642 |
| Taiho Oncology, Inc. | 13 | $761,498 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 20 | $473,685 |
| Merck | 5 | $315,298 |
| AbbVie | 4 | $92,851 |
| Coherus Oncology, Inc. | 21 | $51,162 |
| Boehringer Ingelheim Espana S.A. | 53 | $2,494 |
| Intuitive Surgical | 1 | $1,500 |
| Novocure Inc. | 2 | $231 |
| Galvanize Therapeutics, Inc | 1 | $198 |
| E.r. Squibb & Sons, L.L.C. | 10 | $156 |
| Lilly USA, LLC | 4 | $142 |
| AstraZeneca(2 entities) | 4 | $133 |
| Seagen Inc. | 1 | $126 |
| Bristol Myers Squibb | 5 | $122 |
| Johnson & Johnson | 1 | $117 |
| Sanofi | 5 | $113 |
| Aadi Bioscience, Inc. | 1 | $105 |
| Pfizer | 6 | $104 |
| Sanofi-aventis U.S. LLC | 2 | $99 |
| Amgen | 4 | $97 |
| Deciphera Pharmaceuticals Inc. | 3 | $97 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $88 |
| Exelixis Inc. | 3 | $73 |
| Mirati Therapeutics, Inc. | 2 | $67 |
| Incyte Corporation | 3 | $62 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $45 |
| Stemline Therapeutics Inc. | 2 | $38 |
| Daiichi Sankyo Inc. | 1 | $31 |
| Eisai Inc. | 1 | $21 |
| Musculoskeletal Transplant Foundation Inc. | 1 | $9 |
How this compares
$2,716,401 in reported general payments places this provider in the 85th percentile of 379 medical oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Duarte
- Marwan FakihDuarte$24.2M
- Sumanta PalDuarte$15.9M
- Daneng LiDuarte$12.4M
- Tanya DorffDuarte$8.7M
- Erminia MassarelliDuarte$7.2M
- Joseph ChaoDuarte$4M
- Karen ReckampDuarte$3.1M
- Yan XingDuarte$2.8M
- Marianna KoczywasDuarte$2.3M
- Dani CastilloDuarte$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.